An interventional study of Computerized Plasticity-Based Adaptive Cognitive Training and Commercially available computerized training in Schizophrenia, sponsored by Posit Science Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-07-23.
Sponsored by Posit Science Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.
Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 977th largest by enrollment of the 1,319 interventional ones that give a count, is one of 48 that started in 2018, is one of 479 with no phase, and was the 1,038th registered.
3,567 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18–55
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
University of Wisconsin, Madison · Sites in United States
Ages 18–50 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,465 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 228 · Phase 2 271 · Phase 3 218 · Phase 4 193
First in 1983; this study’s year is marked. 48 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 1,319 interventional studies, 163 across the 128 observational. Of the 1,234 that completed or were terminated, 603 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
516 of 1,465 have an industry lead sponsor. The 10 most frequent:
Posit Science Corporation is the lead sponsor of 36 studies on the registry; 1 is open to participants now.
Posit Science Corporation has 4 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
52 of the studies in Schizophrenia with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT07184619Phase 3Newron Pharmaceuticals SPAEvenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | 2027-03-31 |
| NCT07363577Phase 3LB Pharmaceuticals Inc.Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | 2027-06 |
Add all 52 to your calendar (.ics) → With an account.
Among the 1,465 studies in Schizophrenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a validation study to evaluate the acceptability, feasibility and impact of a mobile psychosocial intervention to enhance social functioning in people with schizophrenia.
The goal of this study is to employ an innovative and evidence-based mobile intervention that includes a neuroscience-informed computerized social cognition training program, a Health Insurance Portability and Accountability Act-compliant videoconferencing tool that we will use for psychoeducational group therapy, and peer-to-peer secure social networking for individuals with schizophrenia, in a parallel arm, double-blind, randomized, controlled clinical trial to assess feasibility and initial efficacy, to investigate the intervention's effects on symptoms, social cognition, and quality of life, and to prepare for a large-scale efficacy trial in adults with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Computerized cognitive training for 18 hours and structured social skills training for 9 hours over a 9 week period.
Other: Computerized Plasticity-Based Adaptive Cognitive Training · Other: Optimized social skills training
Commercially-available computerized training for 18 hours and 9 hours of unstructured support group sessions over a 9 week period.
Other: Commercially available computerized training · Other: Unstructured support group sessions
Training on computerized exercises that targets social cognition for 2 hours per week.
Training on computerized, casual video games for 2 hours per week.
Group-video calls with Specialist for 1 hour per week where participants can interact with Specialist individually or as a group. Specialist will provide guidance, support and feedback, and send links and articles about information and topics discussed during the video calls.
Unstructured support group-video calls for 1 hour per week. The Specialist will not engage with participants (eg. providing participants with links to articles and additional support) or provide guidance for the group discussion.
Social Functioning utilizing the Social Functioning Scale.
Between-group magnitude of change in social functioning utilizing the Social Functioning Scale. The Social Functioning Scale (SFS) was constructed specifically to tap areas of social functioning that are crucial to the community maintenance of individuals with schizophrenia. The 7 domains include: social engagement/withdrawal, interpersonal behavior, pro-social activities, recreation, independence-competence, independence-performance, and employment/occupation. The raw scores for each domain are converted to scaled scores, with a mean of 100 and a standard deviation of 15. Higher scores are indicative of greater social functioning.
Time frame: At 9 weeks
Negative Symptoms utilizing the Positive and Negative Syndrome Scale.
Between-group magnitude of change in negative symptoms utilizing the Positive and Negative Syndrome Scale. The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of patients with schizophrenia. A rating from 1 to 7 is given to each of the 30 different symptoms. The 7-point rating represents increasing levels of psychopathology: 1= absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, and 7=extreme. Of the 30 items included in the PANSS, 7 constitute a Positive Scale, 7 a Negative Scale, and the remaining 16 a General Psychopathology Scale. The scores for these scales are arrived at by summation of ratings across component items. Therefore, the potential ranges are 7 to 49 for the Positive and Negative Scales, and 16 to 112 for the General Psychopathology Scale. Higher scores are indicative of greater symptomatology.
Time frame: At 9 weeks
Quality of Life utilizing the Abbreviated Quality of Life Scale.
Between-group magnitude of change in quality of life utilizing the Abbreviated Quality of Life Scale. The Quality of Life Scale (QLS) is a scale commonly used as a measure of functioning in schizophrenia. The Abbreviated QLS (aQLS) includes 7 items representing all four interdependent theoretical constructs of the original 21-item QLS. Behavioral anchors are presented for each item, scored on a 0 (severe impairment) to 6 (high functioning) scale. Higher scores are indicative of greater quality of life.
Time frame: At 9 weeks
Ran from Apr 2018 to primary completion in May 2019, 13 months.
Of 769 interventional studies with no phase under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.